{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:38:06Z","timestamp":1781725086593,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Millennium\/Takeda Oncology"},{"name":"Millenium\/Takeda Oncology"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.clml.2018.10.006","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T22:44:42Z","timestamp":1539729882000},"page":"48-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Stephen D.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Gandhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathima","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Kanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.10.006_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.10.006_bib2","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.10.006_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.10.006_bib4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.10.006_bib5","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.10.006_bib6","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":"Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation","volume":"29","author":"Budde","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.10.006_bib7","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive 1st-line immunochemotherapy and autologous stem-cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.10.006_bib8","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.clml.2017.11.002","article-title":"Efficacy of standard dose R-CHOP alternating with R-HDAC followed by autologous hematopoietic cell transplantation as initial therapy of mantle cell lymphoma, a single-institution experience","volume":"18","author":"Sawalha","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.10.006_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14480","article-title":"RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106","volume":"176","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.10.006_bib10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3109\/10428194.2010.551154","article-title":"Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma","volume":"52","author":"Hill","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.10.006_bib11","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.10.006_bib12","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.10.006_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V112.11.265.265","article-title":"VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network (ASH Annual Meeting Abstracts)","volume":"112","author":"Kahl","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.10.006_bib14","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.10.006_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2010.08315.x","article-title":"Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma","volume":"151","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.10.006_bib16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13818","article-title":"Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601","volume":"172","author":"Till","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.10.006_bib17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.10.006_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.10.006_bib19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.10.006_bib20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1080\/10428194.2017.1365855","volume":"59","author":"Drach","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.10.006_bib21","first-page":"1","article-title":"Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study","author":"Robak","year":"2017","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018312035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018312035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:38Z","timestamp":1761870758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018312035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2152265018312035"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.10.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}